Todd Neale

The results reinforce existing guidelines that advise pulling back on antithrombotic therapy in the chronic phase.

Though there are limitations, the sham-controlled trial shows “no clinically relevant placebo effect,” a researcher says.

An early CV benefit was apparent, although there's still some question about the longer-term impact versus culprit-only PCI.

The trial shows that a relaxed approach is no worse than proactively keeping serum levels in the high-normal range.

When measured objectively, baseline adherence was “much, much worse” than expected in this first trial from the ESC.

The recommendations have been trimmed down and restructured with an eye toward easier implementation.

The trial was set up to give DCBs their “best shot” in this patient group, says one researcher, but it's tough to beat current DES.

NHANES data affirm that millions of Americans have uncontrolled BP, with most not even aware there's a problem.

These RCT findings support safety and efficacy in 6 to 12 year olds, but there are many unanswered questions, one expert says.

While awaiting more definitive RCTs, it would be reasonable to exclude the LAA in some of these patients, one expert says.